Robinson Capital Management’s Ibere Pharmaceuticals IBER Stock Holding History

Robinson Capital Management’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9,557	Closed	-$96.4K	–	360
2022 Q4	$96.4K	Hold	9,557	–	–	0.05%	194
2022 Q3	$95K	Hold	9,557	–	–	0.08%	202
2022 Q2	$94K	Sell	9,557 -8,324	-47%	-$81.6K	0.07%	176
2022 Q1	$175K	Hold	17,881	–	–	0.12%	153
2021 Q4	$174K	Buy	17,881 +1,348	+8%	+$13.1K	0.11%	125
2021 Q3	$160K	Buy	+16,533	New	+$160K	0.14%	74

Robinson Capital Management's IBER Position: Q1 2023 in Review

Robinson Capital Management sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 9,557 shares — an estimated $96.4K sold.

Robinson Capital Management first reported a position in IBER in Q3 2021 and held it in 6 quarters. The position peaked at $175K in Q1 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Robinson Capital Management reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Robinson Capital Management sold 9,557 Ibere Pharmaceuticals shares in Q1 2023, an estimated $96.4K.
Robinson Capital Management first reported a position in Ibere Pharmaceuticals in Q3 2021 and held it in 6 quarters.
Robinson Capital Management's Ibere Pharmaceuticals position peaked at $175K in Q1 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Robinson Capital Management's 13F filing for Q1 2023, filed 10 May 2023.